在 CLL 和 MBL 患者中，多次接种 COVID-19 疫苗以达到最大抗体反应，可显著降低死亡率和住院率。

Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.

机构信息

Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Kolling Institute, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.

出版信息

Br J Haematol. 2024 Feb;204(2):487-491. doi: 10.1111/bjh.19087. Epub 2023 Sep 5.

DOI:10.1111/bjh.19087

PMID:37669920

Abstract

We analysed COVID-19 infection outcomes of 129/241 chronic lymphocytic leukaemia (CLL) (53.9%) and 22/55 monoclonal B-lymphocytosis (MBL) (40.0%) patients following multiple vaccine doses aiming for maximum measured anti-spike antibody response. Throughout the pandemic to date, there were 8/129 CLL (6.2%) patients hospitalised, with one death (0.8%). No MBL patients were hospitalised or died. CLL patients with COVID-19 had lower anti-spike levels (3778.8 AU/mL) than those without (13 486.8 AU/mL; p = 0.0061). Anti-nucleocapsid antibody was detected in 29.8% within 2 months and 17.5% >6 months. Of COVID-19-infected CLL patients, 47.3% received anti-viral therapy. A multiple vaccine dosing strategy to achieve measured maximum antibody is highly effective in preventing severe COVID-19.

摘要

我们分析了 129/241 例慢性淋巴细胞白血病（CLL）（53.9%）和 22/55 例单克隆 B 淋巴细胞增多症（MBL）（40.0%）患者的 COVID-19 感染结果，这些患者接受了多次疫苗接种，旨在获得最大的抗刺突抗体反应。迄今为止，在整个大流行期间，有 8/129 例 CLL（6.2%）患者住院，其中 1 例死亡（0.8%）。没有 MBL 患者住院或死亡。患有 COVID-19 的 CLL 患者的抗刺突水平（3778.8 AU/mL）低于未患有 COVID-19 的患者（13486.8 AU/mL；p=0.0061）。在 2 个月内检测到 29.8%的抗核衣壳抗体，在 6 个月后检测到 17.5%的抗核衣壳抗体。在感染 COVID-19 的 CLL 患者中，47.3%接受了抗病毒治疗。多次疫苗接种策略以达到可衡量的最大抗体水平，可有效预防严重的 COVID-19。